ArticleFrontiers in neurology
Utilization of screening for cerebrotendinous xanthomatosis in adult patients with idiopathic ataxia.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disorder. Early diagnosis and bile acid replacement therapy can improve prognosis. While clinical presentation typically occurs at a young age, recent data suggests patients presenting as adults may predominately have neurological symptoms, including ataxia. CTX prevalence among adults with idiopathic ataxia is unknown. Methods: In this study, we examined the prevalence of CTX among adult patients with idiopathic ataxia referred to a specialized ataxia clinic. We used serum blood 7α,12α-dihydroxy-4-cholesten-3-one to screen for CTX in adults presenting to our tertiary care ataxia clinic with progressive cerebellar ataxia of unknown etiology. Clinical assessment included the Scale for Assessment and Rating of Ataxia (SARA) and the CTX suspicion index score. 51 participants enrolled, and 50 samples were able to be analyzed. Results: All 50 usable blood samples showed normal 7α,12α-dihydroxy-4-cholesten-3-one levels. Discussion: CTX is a very rare cause of progressive cerebellar ataxia in a tertiary care adult ataxia clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.